Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Macy's Inc (M) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Macy's Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Macy's Inc trades at $22.6 (market cap $5.96B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.7× Macy's Inc's market cap, and Macy's Inc pays a 3.38% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | M | |
|---|---|---|
Market Cap | $39.89B | $5.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $25.96 |
52-Week Low | $278.09 | $11.90 |
Enterprise Value | $38.15B | $9.77B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Macy's (M) trades at $22.64, down 0.18% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows attractive valuation metrics including a P/E of 9.36 and P/S of 0.27, while profitability metrics like ROE of 14.36% indicate efficient capital use. Recent news highlights Berkshire Hathaway's new 3.04 million-share stake and the company's 'Bold New Chapter' strategy driving comparable sales growth.
The outlook for Macy's is cautiously optimistic with a consensus price target of $24.83 offering ~10% upside. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from restructuring and competitive retail headwinds. The stock presents a value opportunity if turnaround execution continues successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
